Roberto Bellini is currently a Managing Partner at BSQUARED Capital, a family office biotech fund.
He served as President and CEO of BELLUS Health between January 2010 and July 2023. Under his leadership, BELLUS Health developed a P2X3 antagonist, camlipixant, for
chronic cough from preclinical to Phase 3 and was acquired by GSK plc for US$2.0B in 2023.
Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.
Roberto Bellini served as President and CEO of BELLUS Health between January 2010 and July 2023. Under his leadership, BELLUS Health developed a P2X3 antagonist, camlipixant, for chronic cough from preclinical to Phase 3 and was acquired by GSK plc for US$2B in 2023. Mr. Bellini previously oversaw the licensing and partnering activities of BELLUS Health.
His experience includes several roles and responsibilities at Picchio Pharma Inc., a joint venture healthcare investment firm owned by the Bellini Family Trust and Power Corporation of Canada, and its investee companies.
Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.